A Comparative Study of the Antihypertensive Agents on Serum Liver Enzymes ALT, AST and ALP of Hypertensive and cardiac Patients

Abstract

Present study is done to compare serum Liver enzymes including Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Alkaline Phosphatase (ALP) in hypertensive and cardiac patients. 24 patients were divided into 4 groups according to their treatment with 4 different types of antihypertensive drugs. Group I treated with Beta-blockers (1+1). Group II treated with ACE-Inhibitor once a day. Group III treated with Nitrates once a day. Group IV is taking Diuretics once a day. Data showed non-significant difference in serum ALT concentration in all groups. A significant rise (p< 0.05) in serum AST and ALP levels among hypertensive and cardiac patients is observed, ranging from 24.63-47.33U/L and 110-2484 U/L respectively when compared with normal controls. Thus, not only the risk of cardiac diseases in future might be predicted by altered levels of enzymes ALT, AST and ALP in serum but their concentrations should be monitored during the treatment of cardiac diseases to minimize the risk of cardiac arrest.

Simultaneous determination of metformin and glibenclamide by RP-HPLC in orodispersible tablets and their pharmacokinetic evaluation

“…The most common gastrointestinal disorders associated with it are anorexia, nausea, diarrhea, epigastric fullness, heartburn and dyspepsia. The adverse reactions reported with use of sulfonylureas are anemia, hemolytic anemia, thrombocytopenia, leucopenia, agranulocytosis and bone marrow aplasia (Javaid, Hasan, Zaib, & Mansoor, 2007). The metformin and glibenclamide are recommended in combination due to inefficiency of monotherapy as it can deal not only with insulin resistance but also with beta cell dysfunction.…”